{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:27:21Z","timestamp":1790753241334,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1186","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZB20240865"],"award-info":[{"award-number":["GZB20240865"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically synthesize evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and imaging biomarkers of subclinical atherosclerosis and hepatic steatosis\/fibrosis, and to quantify the magnitude of these associations across study populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Web of Science Core Collection, and Cochrane Library (January 2000-February 28, 2026) for observational studies enrolling adults with MASLD (or historical NAFLD\/MAFLD) that reported atherosclerotic cardiovascular disease (ASCVD)-related imaging outcomes. Primary outcomes were continuous coronary artery calcium (CAC; Agatston units), epicardial adipose tissue (EAT; cm3), controlled attenuation parameter (CAP; dB\/m), and liver stiffness measurement (LSM; kPa). Weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for dichotomized thresholds were pooled using random-effects models with restricted maximum likelihood (REML) estimation and Hartung-Knapp adjustment where applicable; heterogeneity was quantified with I2 and \u03c42.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen observational studies (n\u2009=\u200934\u00a0713; 6 cohorts, 10 cross-sectional) from North America, Asia, and Europe were included. In modality-specific threshold analyses, MASLD was associated with higher odds of subclinical disease: CAC (OR 1.41, 95% CI: 1.32-1.51; I2 = 75.0%), high EAT (OR 1.44, 95% CI: 1.21-1.68; I2 = 0%), high CAP (OR 1.47, 95% CI: 1.35-1.58; I2 = 0%), and high LSM (OR 1.49, 95% CI: 1.31-1.66; I2 = 0%). For continuous outcomes, CAC was higher by 49.2 Agatston units (95% CI: 46.8-51.7; I2 = 75.4%) and LSM was higher by 0.57\u2009kPa (95% CI: 0.46-0.68; I2 = 0%) in MASLD versus comparators. EAT (k\u2009=\u20092; n\u2009=\u20094306): WMD 76.18\u2009cm\u00b3 (95% CI: 5.04-147.32; I2 = 98.3%) (exploratory only; not suitable for point estimation). CAP (k\u2009=\u20092; n\u2009=\u20096652): WMD 45.12\u2009dB\/m (95% CI: 0.96-89.27; I2 = 98.1%) (exploratory only; not suitable for point estimation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MASLD is consistently associated with greater calcific coronary burden, pericoronary adiposity, hepatic steatosis, and hepatic stiffness relative to non-MASLD comparators. These findings represent between-group imaging differences and should be interpreted as evidence of concurrent adverse imaging burden rather than formal demonstration of incremental predictive value beyond validated clinical risk engines. Whether these biomarkers improve discrimination, reclassification, or net clinical benefit beyond established scores (Pooled Cohort Equations [PCE], SCORE2, Framingham Risk Score [FRS]) requires prospective validation with pre-specified incremental prediction analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>This study provides a comprehensive quantitative, multimodality synthesis demonstrating that MASLD is consistently associated with concurrent adverse changes across 4 key imaging biomarkers spanning subclinical atherosclerosis (CAC, EAT) and hepatic disease burden (CAP, LSM), establishing a critical evidence base to motivate prospective studies on integrating standardized imaging protocols to refine ASCVD risk characterization in MASLD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag112","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:31:30Z","timestamp":1779024690000},"page":"2035-2053","source":"Crossref","is-referenced-by-count":1,"title":["Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores"],"prefix":"10.1093","volume":"99","author":[{"given":"Jiaxin","family":"Zhong","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University , Changsha, Hunan Province 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifen","family":"He","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University , Changsha, Hunan Province 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University , Changsha, Hunan Province 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University , Changsha, Hunan Province, 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Cai","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University , Changsha, Hunan Province 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026092915470323300_tqag112-B1","doi-asserted-by":"publisher","first-page":"1469492","DOI":"10.3389\/fcvm.2024.1469492","article-title":"Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress","volume":"11","author":"Minetti","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026092915470323300_tqag112-B2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/00365521.2025.2536585","article-title":"Cardiovascular implications of MASLD: overview of the evidence","volume":"60","author":"Ismail","year":"2025","journal-title":"Scand J Gastroenterol"},{"key":"2026092915470323300_tqag112-B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","article-title":"Metabolic dysfunction-associated steatotic liver disease and atherosclerosis","volume":"24","author":"Castillo-N\u00fa\u00f1ez","year":"2024","journal-title":"Curr Diab Rep"},{"key":"2026092915470323300_tqag112-B4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"key":"2026092915470323300_tqag112-B5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2023.07.008","article-title":"Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: results from the multi-ethnic study of atherosclerosis","volume":"265","author":"Ichikawa","year":"2023","journal-title":"Am Heart J"},{"key":"2026092915470323300_tqag112-B6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11883-023-01161-8","article-title":"Coronary and extra-coronary subclinical atherosclerosis to guide lipid-lowering therapy","volume":"25","author":"Grant","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2026092915470323300_tqag112-B7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3978\/j.issn.2223-3652.2014.11.05","article-title":"Epicardial adipose tissue: far more than a fat depot","volume":"4","author":"Talman","year":"2014","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026092915470323300_tqag112-B8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.atherosclerosis.2014.01.038","article-title":"Prognostic value of coronary artery calcium and epicardial adipose tissue assessed by non-contrast cardiac computed tomography","volume":"233","author":"Kunita","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026092915470323300_tqag112-B9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2011.09.041","article-title":"Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis","volume":"220","author":"Yerramasu","year":"2012","journal-title":"Atherosclerosis"},{"key":"2026092915470323300_tqag112-B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12933-021-01220-x","article-title":"Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026092915470323300_tqag112-B11","doi-asserted-by":"publisher","first-page":"e0202666","DOI":"10.1371\/journal.pone.0202666","article-title":"Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a cross-sectional, population-based study in middle-aged subjects","volume":"13","author":"Gummesson","year":"2018","journal-title":"PLoS One"},{"key":"2026092915470323300_tqag112-B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/apt.17637","article-title":"Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes","volume":"58","author":"Kuo","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092915470323300_tqag112-B13","doi-asserted-by":"publisher","first-page":"2486594","DOI":"10.1080\/07853890.2025.2486594","article-title":"Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk","volume":"57","author":"Gui","year":"2025","journal-title":"Ann Med"},{"key":"2026092915470323300_tqag112-B14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12933-025-02764-y","article-title":"Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with type 1 diabetes and metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Mertens","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026092915470323300_tqag112-B15","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1111\/jgh.15523","article-title":"Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population","volume":"36","author":"Pennisi","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2026092915470323300_tqag112-B16","doi-asserted-by":"publisher","first-page":"e016465","DOI":"10.1161\/CIRCIMAGING.123.016465","article-title":"Impact of nonalcoholic hepatic steatosis on the warranty period of a coronary artery calcium score of 0: results from the multi-ethnic study of atherosclerosis","volume":"17","author":"Ichikawa","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026092915470323300_tqag112-B17","doi-asserted-by":"publisher","first-page":"e0269265","DOI":"10.1371\/journal.pone.0269265","article-title":"A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis","volume":"17","author":"Bessho","year":"2022","journal-title":"PLoS One"},{"key":"2026092915470323300_tqag112-B18","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1210\/jc.2016-1525","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study","volume":"101","author":"Park","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092915470323300_tqag112-B19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hep.25593","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification","volume":"56","author":"Kim","year":"2012","journal-title":"Hepatology"},{"key":"2026092915470323300_tqag112-B20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/apt.16324","article-title":"Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092915470323300_tqag112-B21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13098-025-01577-z","article-title":"Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in Eastern China","volume":"17","author":"Ma","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"2026092915470323300_tqag112-B22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2147\/TCRM.S168345","article-title":"Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population","volume":"14","author":"Meng","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2026092915470323300_tqag112-B23","doi-asserted-by":"publisher","first-page":"22917","DOI":"10.1038\/s41598-024-74287-7","article-title":"Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification","volume":"14","author":"Kang","year":"2024","journal-title":"Sci Rep"},{"key":"2026092915470323300_tqag112-B24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/diagnostics14202305","article-title":"Visceral obesity and its association with severe coronary artery calcification in patients with metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Kang","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026092915470323300_tqag112-B25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/biomedicines11030883","article-title":"From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications","volume":"11","author":"Boccatonda","year":"2023","journal-title":"Biomedicines"},{"key":"2026092915470323300_tqag112-B26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2026092915470323300_tqag112-B27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17446651.2025.2492767","article-title":"MAFLD vs. MASLD: a year in review","volume":"20","author":"Jiang","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026092915470323300_tqag112-B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-0044-1785196","article-title":"New nomenclature for nonalcoholic fatty liver disease: understanding metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction- and alcohol-associated liver disease, and their implications in clinical practice","volume":"44","author":"Canivet","year":"2024","journal-title":"Semin Liver Dis"},{"key":"2026092915470323300_tqag112-B29","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.dld.2016.09.002","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis","volume":"48","author":"Jaruvongvanich","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2026092915470323300_tqag112-B30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep4.1199","article-title":"Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis","volume":"2","author":"Kapuria","year":"2018","journal-title":"Hepatol Commun"},{"key":"2026092915470323300_tqag112-B31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J Hepatol"},{"key":"2026092915470323300_tqag112-B32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/ajcp\/93.6.754","article-title":"Fine-needle aspiration of non-Hodgkin\u2019s lymphoma. Southern blot analysis for antigen receptor, bcl-2, and c-myc gene rearrangements","volume":"93","author":"Williams","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"2026092915470323300_tqag112-B33","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"2026092915470323300_tqag112-B34","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.3390\/ijms20235989","article-title":"Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk","volume":"20","author":"Villasante","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026092915470323300_tqag112-B35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/ceh.2023.130744","article-title":"Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor","volume":"9","author":"Platek","year":"2023","journal-title":"Clin Exp Hepatol"},{"key":"2026092915470323300_tqag112-B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2021.04.011","article-title":"Utilizing coronary artery calcium to guide statin use","volume":"326","author":"Golub","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026092915470323300_tqag112-B37","doi-asserted-by":"publisher","first-page":"n776","DOI":"10.1136\/bmj.n776","article-title":"Role of coronary artery calcium score in the primary prevention of cardiovascular disease","volume":"373","author":"Nasir","year":"2021","journal-title":"BMJ"},{"key":"2026092915470323300_tqag112-B38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2018.05.013","article-title":"Comparison of epicardial adipose tissue radiodensity threshold between contrast and non-contrast enhanced computed tomography scans: a cohort study of derivation and validation","volume":"275","author":"Xu","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026092915470323300_tqag112-B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092915470323300_tqag112-B40","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"2026092915470323300_tqag112-B41","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag112\/68302712\/tqag112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1186\/2035\/68302712\/tqag112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1186\/2035\/68302712\/tqag112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:47:08Z","timestamp":1790711228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1186\/2035\/8680200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":41,"journal-issue":{"issue":"1186","published-online":{"date-parts":[[2026,5,15]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag112","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,15]]}}}